Acoustic Neuroma Diagnosis and Treatment Decisions

Quick answer: Acoustic neuroma, also called vestibular schwannoma, is a usually benign tumour arising from Schwann cells around the balance-and-hearing nerve. Common patterns include hearing loss in one ear, one-sided tinnitus and imbalance, but symptoms alone cannot confirm or exclude it. Audiometry and clinician-selected MRI are used when the history and hearing pattern warrant investigation.

Evidence reviewed/updated: 31 August 2026.

What acoustic neuroma means

Vestibular schwannoma is the preferred medical name. “Benign” means that it is not a cancer that spreads to distant organs; it does not mean that every tumour is harmless. Its location near the hearing, balance and facial nerves means that size, growth, symptoms and treatment risks still matter.

This page focuses on diagnosis and management decisions. For a symptom-first overview, use the separate acoustic neuroma hearing and balance guide.

Possible symptoms

• unilateral or asymmetric sensorineural hearing loss;
• tinnitus, often more noticeable in one ear;
• imbalance, unsteadiness or dizziness;
• reduced speech understanding in the affected ear; and
• facial numbness, weakness or other pressure effects in some larger or anatomically significant tumours.

These symptoms are not specific to a tumour. Most people investigated for asymmetric hearing loss or unilateral tinnitus do not have a vestibular schwannoma. Symptom intensity also does not reliably predict tumour size.

When to seek faster assessment

Sudden hearing loss is an urgent medical problem, whether or not a tumour is suspected. Seek urgent assessment for hearing that drops suddenly over hours or a few days. New facial weakness or numbness, double vision, slurred speech, severe headache, collapse, inability to walk safely or another acute neurological change also needs prompt emergency assessment rather than a routine appointment.

How the diagnosis is investigated

History, ear examination and audiometry

The clinician asks about onset, progression, tinnitus, dizziness, neurological symptoms, noise exposure, medicines and previous hearing results. Pure-tone and speech audiometry help document the type and asymmetry of hearing loss. There is no single hearing threshold that diagnoses a vestibular schwannoma; MRI decisions use the complete clinical and audiological context.

MRI

High-resolution MRI of the internal auditory canals and cerebellopontine angle is the diagnostic imaging test when a structural lesion needs to be assessed. MRI can demonstrate a vestibular schwannoma and its anatomical relationships, but it does not by itself decide whether observation, radiation or surgery is best.

The 2026 Congress of Neurological Surgeons audiological review found a low MRI yield for vestibular schwannoma among people investigated for sensorineural hearing loss, unilateral tinnitus or sudden hearing loss. That supports appropriate investigation without telling every person with tinnitus that a tumour is likely.

Management is individualized

The main pathways are observation with follow-up, stereotactic radiosurgery or fractionated radiotherapy, and microsurgery. The choice depends on tumour size and location, documented growth, symptoms, useful hearing, age, general health, patient priorities and the experience of the treating multidisciplinary team.

Observation

Observation may be appropriate for selected small, minimally symptomatic or stable tumours. Follow-up MRI and audiometry are individualized; a universal six- or twelve-month schedule is not appropriate for every untreated or treated tumour. A change in hearing or balance should be reported rather than waiting automatically for the next scan.

Radiation

Stereotactic radiosurgery aims to control tumour growth rather than physically remove the tumour. Results vary with tumour and patient selection, dose, follow-up duration and the outcome being measured. It should not be described to an individual as a guaranteed “95% cure,” and hearing preservation cannot be promised.

Microsurgery

Microsurgery may be considered for growing, symptomatic or larger tumours and in other situations where removal offers the best balance of benefits and risks. The surgical approach and the possibility of hearing or facial-nerve preservation depend on anatomy, tumour characteristics, baseline function and specialist judgment.

Hearing and balance rehabilitation

Support may include conventional hearing aids, CROS or BiCROS systems, bone-conduction devices or, for selected patients, cochlear implantation. The choice depends on residual hearing, speech discrimination, cochlear-nerve function and tumour treatment. Vestibular rehabilitation may help selected patients with persistent imbalance. No device or exercise can be promised to restore normal hearing or balance.

August 2026 evidence update

No August 2026 guideline replaced the established individualized management approach. Three newly published observational studies add narrow information rather than a new rule for all patients:

• SRS in octogenarians: an international retrospective cohort included 309 patients aged 80 or older treated with single-fraction stereotactic radiosurgery. The findings support SRS as one possible option for carefully selected older adults, but there was no observation or surgery comparator and the results do not apply automatically to younger patients or every tumour size. Original DOI; PubMed 42566794.
• Quality of life after a retrolabyrinthine operation: a retrospective tertiary-centre study followed 59 operated patients using PANQOL. Overall scores were stable or improved through two years, while hearing and balance scores temporarily worsened in the subgroup whose hearing deteriorated. Without an untreated control group, this cannot predict an individual patient’s result. Original DOI; PubMed 42550582.
• Research on MRI changes after SRS: a preliminary retrospective study analysed 85 patients and 170 post-SRS MRI scans. It examined internal tumour growth and an investigational segmentation model; it does not establish a patient-accessible AI diagnostic test or replace expert MRI review. Original DOI; PubMed 42584671.

Frequently asked questions

Is acoustic neuroma cancer?

It is usually a benign schwannoma and does not metastasize like a malignant cancer. Local effects can still matter, so specialist review is based on anatomy, growth, symptoms and function.

Does one-sided tinnitus mean I have a tumour?

No. Unilateral tinnitus has many possible causes. It deserves an appropriate ear and hearing assessment, and MRI is selected when the full pattern meets clinical criteria.

Can a small tumour always be observed?

No single size creates an automatic plan. Observation is common for selected patients, but growth, symptoms, useful hearing, age, health and patient preference can change the decision.

Is surgery the only treatment?

No. Depending on the case, observation, stereotactic radiosurgery, fractionated radiotherapy or microsurgery may be considered. The goal is shared decision-making, not a one-size-fits-all pathway.

Can MRI distinguish vestibular schwannoma from Ménière disease?

MRI can identify or exclude many structural lesions. Ménière disease remains a clinical diagnosis supported by hearing findings and the attack pattern; one scan does not by itself explain every hearing or balance symptom.

Related guides

• Acoustic neuroma symptoms and hearing changes
• Audiogram explained
• MRI for dizziness and vertigo
• Vertigo diagnosis guide

References

1. Goldbrunner R, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro-Oncology. 2020;22:31–45. doi:10.1093/neuonc/noz153; full text.
2. Strickland BA, et al. Congress of Neurological Surgeons systematic review and evidence-based guideline on audiologic screening. Neurosurgery. 2026;98:278–282. doi:10.1227/neu.0000000000003426; PubMed.
3. Graffeo CS, et al. Congress of Neurological Surgeons systematic review and evidence-based guideline on imaging. Neurosurgery. 2026;98:283–287. doi:10.1227/neu.0000000000003419; PubMed.
4. Germano IM, et al. Congress of Neurological Surgeons systematic review and guideline on stereotactic radiosurgery. Neurosurgery. 2026;98:293–297. doi:10.1227/neu.0000000000003416; PubMed.
5. Van Gompel JJ, et al. Congress of Neurological Surgeons systematic review and evidence-based guideline on surgical resection. Neurosurgery. 2026;98:272–277. doi:10.1227/neu.0000000000003473; PubMed.
6. Mankekar G, Holmes S. Hearing rehabilitation in vestibular schwannoma. Audiology Research. 2023;13:357–366. doi:10.3390/audiolres13030031; full text.
7. National Institute on Deafness and Other Communication Disorders. Vestibular schwannoma (acoustic neuroma) patient information.
8. Abou-Al-Shaar H, et al. Stereotactic radiosurgery for vestibular schwannoma in octogenarians. J Neurosurg. Published online 7 August 2026. doi:10.3171/2026.2.JNS252486.
9. Wakabayashi M, et al. Quality of life after the retrolabyrinthine approach. Otol Neurotol. Published online 4 August 2026. doi:10.1097/MAO.0000000000005025.
10. Chung M, et al. Volumetric assessment of internal growth after stereotactic radiosurgery. Clin Neuroradiol. Published online 12 August 2026. doi:10.1007/s00062-026-01707-8.

Medical disclaimer: This article is general education, not an individual diagnosis, treatment recommendation or outcome guarantee. Sudden hearing loss and acute neurological warning signs need urgent medical assessment.